Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Becton Dickinson buys CR Bard for $24 billion to form medical supply giant. Bard shareholders received $222.93 in cash and 0.5077 shares of Becton Dickinson…
Evercore IS analyst Vijay Kumar said the deal would make BD an indispensable partner to hospitals as changing industry dynamics drive customer consolidation
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Becton Dickinson acquired C.R. Bard for approximately $24 billion in cash and stock ($222.93 in cash and 0.5077 BD shares per Bard share). The combination created a healthcare leader with approximately $16 billion in annualized revenue.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Becton, Dickinson and Company / C.R. Bard Inc. (this deal) | 2017 | $24.0B | 77 |
| Thermo Fisher Scientific Inc. / Life Technologies Corporation | 2013 | $15.1B | 84 |
| Merck KGaA / Sigma-Aldrich Corporation | 2014 | $17.0B | 80 |
| Johnson & Johnson / Synthes Inc. | 2011 | $19.7B | 77 |
| Thermo Fisher Scientific Inc. / PPD Inc. | 2021 | $17.4B | 77 |
| Danaher Corporation / GE Life Sciences Biopharma Business (now Cytiva) | 2019 | $21.4B | 76 |
| Roche Holding AG / Halozyme Therapeutics, Inc. | 2017 | $190M | 75 |